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Summary.-Immunological indices have been reassessed in27 patients in remission
from Hodgkin's disease for 5 years after treatment and the findings correlated with
initial treatment and splenectomy status. Neutrophil counts were lower and
lymphocyte and monocyte counts higher at 5 years' remission than at presentation;
the increases in lymphocyte count were mainly a feature of the splenectomized
patients. Neutrophil function (nitro-blue tetrazolium) was unchanged in remission
but cellular immunity (leucocyte migration inhibition and lymphocyte transforma-
tion) was depressed at 5 years and progressive falls in serum immunoglobulins were
noted. Low values of IgG and IgM were particularly found in patients who had
splenectomy and chemotherapy; there was however no excess of infections in this
small group.
THE LONG-TERM EFFECTS of radio-
therapy, chemotherapy and splenectomy
in Hodgkin's disease are not yet fully
established. Cellular immunity may
remain depressed for years after chemo-
therapy (Fisher et al., 1980) and after
radiotherapy long-lived defects in cellular
immunity may also be found (Fuks et al.,
1976; Bjorkholm et al., 1977b), though
Kun & Johnson (1975) found normal
delayed hypersensitivity skin-test
responses 5 years after radical radio-
therapy. Impaired humoral immunity has
been observed in treated Hodgkin's dis-
ease (Weitzman et al., 1977); however,
other reports (Fisher et al., 1980; Kun &
Johnson 1975) suggest that in the long-
term humoral immunity is not depressed.
In 1977 we reported our early follow-up
studies on the immune status of patients
with Hodgkin's disease after splenectomy
and treatment (Hancock et al., 1977).
Cellular immunity as judged by skin tests
and leucocyte migration inhibition showed
little evidence of disturbance after one
year but serum IgG and IgM levels fell
with intensive chemotherapy in splenec-
tomized patients; and IgA and IgM levels
were lower, irrespective of splenectomy or
therapy status, after 1 year's remission
than either at presentation or after
treatment. Twenty-seven of the patients
assessed in that study have been reasses-
sed 5 years after completion of therapy.
All patients entered complete remission
with treatment and remained disease-free
at reassessment. The findings have been
correlated with initial treatment and
splenectomy status.
METHODS
Peripheral blood counts
Total lymphocyte, neutrophil and mono-
cyte counts were performed at each stage of
the assessment.
Neutrophilfunction
The nitro-blue tetrazolium (NBT) test used
was the unstimulated semi-quantitative histo-
chemical technique of Park et al. (1968).
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Heparinized blood was incubated with buf-
fered 0.1% NBT solution. Smears were made
on glass slides and stained. The percentage of
neutrophils containing formazan deposits
were counted. Normally less than 10% of
neutrophils show a reduction.
Cellular immunity
Leucocyte migration inhibition test. he
leucocyte migration inhibition test was modi-
fied from the method of S0berg & Bendixen
(1976). Separated peripheral leucocytes were
allowed to migrate from microcapillary tubes
in wells containing (a) purified protein
derivative, (b) Candida albicans extract and
(c) control medium. Migration areas with
antigens in each experiment were statistically
compared with control migration areas
(Student's t test) and significant inhibition of
migration was said to have occurred if
P<0-05. If significant migration inhibition
occurred with one or both antigens the
patient was considered immunocompetent in
this test. This test was repeated at each stage
of assessment.
Lymphocyte transformation
The lymphocyte transformation was modi-
fied from that of Schellekens & Eijsvoogel
(1968). Lymphocytes were separated from
whole blood by a Ficoll-based centrifugation
method and distributed into triplicate cul-
tures containing culture medium, autologous
plasma and phytohaemaglutinin. Control
healthy lymphocyte cultures were also set up
and all cultures were incubated at 37°C for
72 h. To measure lymphocyte transformation
by estimation of DNA synthesis the lympho-
cytes were labelled with tritiated thymidine
for the last hour of incubation. Synthesis was
then arrested by cooling to 40C and the cells
were harvested. Radioactivity was counted to
give a final result in disintegrations per
minute (d.p.m.). Each patient was assessed
against age and sex-matched control ranges.
Values below these ranges were interpreted
as subnormal. Lymphocyte transformation
assessments were made before treatment and
5 years after treatment.
T-cell counts
A spontaneous E-rosette-formation tech-
nique based on that of Steel et al. (1974) was
used. Washed, fresh, defibrinated, preserva-
tive-free sheep red cells (Gibco Bio-Cult Ltd)
were added to washed, separated lympho-
cytes in culture medium, centrifuged at 200 g
for 5 min and incubated at 4°C for 1 h. After
re-suspension the number and proportion of
rosette-forming lymphocytes was counted in a
haemocytometer. The normal range in our
laboratory for this technique is 40-80%. T-
cell studies were performed at presentation
and at 5 years.
Humoral immunity
Immunoglobulins.-Serum immunoglobu-
lins were determined by automated immuno-
precipitation (the local standard preparation
being calibrated in relationship to the mass
equivalent ofthe IFCC preparation 74/1).
Patients
Twenty-seven patients with Hodgkin's
disease attaining complete remission were
assessed at presentation, immediately after
radiotherapy or before the third or fourth
course of intensive chemotherapy and after 1
and 5 years' remissiotn.
During the period ofstudy it was the policy
ofthe Lymphoma Group in Sheffield, U.K., to
select patients for laparotomy and splenect-
omy on the basis of clinical staging and
histological type. Those patients with Stage
IA and IIA disease of lymphocyte predomin-
ant and nodular sclerosing histology and with
Stage IIIB, IVA, IVB (all histological types)
did not have laparotomy; all other patients
did. Patients with Stage I-IIIA disease had
radical radiotherapy (mantle, inverted Y or
total nodal irradiation); patients with stage
IIIB-IV disease had intensive chemotherapy
(modified MOPP, see appendix).
Of the 27 patients, 15 had undergone
splenectomy and ofthese 7 were subsequently
treated with chemotherapy and 8 with
radiotherapy. Of the 12 patients not under-
going splenectomy, 7 had radiotherapy and 5
had chemotherapy. The clinical details of the
patients according to their treatment/splenec-
tomy status are shown in Table I.
Stati.stical analysis
To reduce the effects of variations in the
basic levels of each quantitative variable
(neutrophils, lympocytes, immunoglobulins)
between the patients the changes at each
stage of assessment for each of the variables
were considered. As a simple first step changes
within the group as a whole were analysed
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TABLE II.-Follow-up assessments of immune status in patients with Hodgkin's disease
in remission
Neutrophil count
Cells x 109/1 (mean + s.e.)
Normal 1 - 5-7 -5
NBT score % (mean+ s.e.)
Normal 1-10
Monocyte count
Cells x 109/1 (mean +s.e.)
Normal 0 2-0 8
Lymphocyte count
Cells x 109/1 (mean+s.e.)
Normal 10 * 4 -0
T cells % (mean+s.e.)
Normal 40-80
PHA % normal
LMI % normal
Immunoglobulins g/l (mean + s.e.)
IgG (normal 7-5-14-0)
IgA (normal 1 0-3 0)
IgM (normal 0.4-1 -6)
Before
treatment
5-32+ 0-53
After
treatment
3-84+0-29*
7-21+0-78 6-0+ 1-14
1 Year
remission
4-49+0-36
5 Years'
remission
3-57+0-34*
5-63+0-31
0-19+0-03 0-28+0-04* 0.35+0.05** 0.40+0.04***
1-70+0-10 1-34+0-14* 1-93+0-17 2-48+0-29*
37-33+3-62
70%
56%
12-34+0-47
2-92+0-30
1- 25 + 0-13
- 53-96+ 2-16*
68%
11-00+0-75
2-20+0-26
0-81+0 12*
57%
11-50+0 76
1 .55+0.15***
0.50+0.05***
33%*
8%**
10-07+0-49***
1 -39+0.12***
0-55+0-06***
*** P <0001; ** P> 0*01; * P < 0*05 (compared with pretreatment values).
separately using paired Student's t and x2
tests (Table II). The patients were then
assessed torelate the relative changes in levels
ofeach ofthe variables to the 2 main factors,
i.e. radiotherapy/chemotherapy and splenec-
tomy/no splenectomy. A 2-way analysis of
variance with interaction with unequal num-
bers ofobservations inthe cells (Scheff6, 1960)
was used. Inspection ofthe data revealed that
the underlying assumption of normality
seemed reasonable.
RESULTS
Leucocyte counts
Neutrophil counts (Fig. 1) in the group
as a whole fell significantly aftertreatment
(P < 0.05), increased by 1 year (P< 0-05)
but were still significantly lower at 5 years'
remission than at presentation (P< 0-05).
This trend was not evident for those
patients who had splenectomy and radio-
therapy (P< 0.01). Lymphocyte counts
(Fig. 1) overall fell after treatment
(P< 0.05) and increased 1 year and at 5
years after treatment (P < 0-01 and 0 001
respectively). This increase was accounted
for by counts in those patients who
underwent splenectomy (P< 0 01). Mono-
cyte counts (Table II) increased after
treatment (P<0.05) at 1 year (P<0.01)
and at 5 years (P < 0-001) compared with
pretreatment values. Individual groups
did not show significantly different values
at any stage.
Neutrophilfunction
There was no significant change in
neutrophil function as assessed by NBT
scores (Table II) after treatment or after 5
years' remission.
Cellular immunity
Leucocyte migration inhibition studies
showed no significant changes after treat-
ment and after 1 year's remission but were
significantly lower (P< 0-01) at 5 years
(Table II). All groups of patients showed
this depression of reactivity. PHA lym-
phocyte transformation was assessed only
at presentation and in remission. The
number ofpatients with normal responses
was however significantly lower (P < 0.05)
at 5 years than at presentation. T-cell
population studies were also assessed at
presentation and after 5 years. There was
an overall increase in both the percentage
and the number of T cells (P < 0 01). This
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FIG. 1.-Alean clhanges in leucocyte;counts from before treatment to following treatment (post)
and to 1 ,year and 5 year assessments. Key: RT, radiotherapy; S, splenectomy; CT, chemo-
thlerapy; NS, no splenectomy.
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FIG. 2. MAean chlanges in serum immunoglobulin levels from before treatment to following treatment
(post) and to 1 year and 5 year assessments. Key: RT, radiotherapy; S, splenectomy; CT, chemo-
therapy; NS, no splenectomy.
was a particular feature of the splenec-
tomized patients though there were no
significant differences between individual
groups.
Humioral irnintuity
All immunoglobulin classes showed falls
during the period of study (Fig. 2). At
presentation, values (particularly IgA) for
the group as a whole were not unexpec-
tedly near the top of the normal ranges.
Individual patients had values above the
normal range (3 IgG, 9 IgA and 5 IgM).
All fell to normal with remission though
2/5 patients with initially raised IgM had
subnormal values at 5 years. In all, at this
stage there were 3, 5 and 7 patients with
subnormal IgG, IgA and 1gM values
respectively. With IgG the 5-year assess-
ment was significantly lower than pre-
treatment and 1-year levels (P < 0 001 and
0 05 respectively). Low values throughout
x109/1
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TABLE III.-Infection observed duringfollow-up
Viral Bacterial
Radiotherapy/non-splenectomy
(7 patients)
Radiotherapy/splenectomy
(8 patients)
Chemotherapy/non-splenectomy
(5 patients)
Chemotherapy/splenectomy
(7 patients)
Herpes zoster/varicella (2)
Herpes zoster/varicella (2)
Herpes simplex Type 2 (1)
Herpes zoster/varicella (2)
Recurrent respiratory (1)
Oral Candida (1)
Recurrent skin (1)
follow-up were seen more frequently in
those patients who had chemotherapy and
splenectomy. IgA levels fell significantly
compared with pretreatment values by 1
year (P < 0 01) and this fall was sustained
at 5 years (P < 0-001). IgM levels fell
significantly with treatment (P < 0*05) and
values at 1 and 5 years' remission were also
significantly lower than at presentation
(P < 0-001); low values throughout follow-
up were a particular feature of the
chemotherapy/splenectomy group.
Correlation with infection (Table III)
The list of infections is not exhaustive,
as trivial nonspecific respiratory and
mucosal infections were not documented.
The only group which stands out is the
radiotherapy/non-splenectomy group, in
which there were no major infections.
Viral infections were not uncommon in the
other groups (particularly with Herpes
zoster/varicella).
DISCUSSION
Changes in the immunological status of
patients with Hodgkin's disease in the
follow-up period after radiotherapy or
chemotherapy are variable. Undoubtedly
radiotherapy and chemotherapy depress
immunity (particularly cellular immunity)
during and for some time after the
conclusion of treatment. Immunity may
return to normal as the patients' general
condition improves after treatment. Kun
& Johnson (1975) were able to show no
evidence of residual haematological or
immunological depression in 71 consecu-
tive patients treated successfully for
Hodgkin's disease by radiotherapy 5 years
previously. In particular the quantitative
immunoglobulin levels were normal and
delayed hypersensitivity reactions were
intact. Fuks et al. (1976), however, in a
study of 26 patients in complete remission
12-111 months after radiation therapy
showed T-cell lymphocytopenia and sig-
nificant impairment of in vitro lympho-
cyte-transformation responses persisting
for as long as 10 years after treatment with
radiotherapy; most of these patients had
had laparotomy with splenectomy.
Bjorkholm et al. (1977a, b) have also
demonstrated persistent defects 15-18
months after radiotherapy and particu-
larly in a group of 9 cured patients (10-28
years after treatment).
It is generally accepted that serious
infections (e.g. septicaemia) occur more
frequently after splenectomy, particularly
where patients have had aggressive treat-
ment of the underlying lymphoma and
Weitzman et al. (1977) showed that
treatment with combined radiotherapy
and chemotherapy impaired humoral de-
fence mechanisms against Haemophilus
influenzae Type B and that serum levels of
IgM were significantly reduced in patients
having chemotherapy and prior splenec-
tomy. Significant reductions in E-rosette
and mitogen-induced proliferation were
also observed in 47 long-term survivors of
Hodgkin's disease who had been success-
fully treated with MOPP chemotherapy
(Fisher et al., 1980); the defects continued
for as long as 11 years.
In our study absolute lymphocyte and
monocyte counts had risen 5 years after
treatment; the T-cell population had also
increased. However, leucocyte-migration-
Other
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inhibition and lymphocyte-transformation
asssessments were significantly lower at 5
years than at presentation, when responses
were already subnormal. Since all these
patients were in clinical remission when
retested, these findings invalidate our
previous suggestion (Hancock et al., 1977)
that deteriorating cellular immunity may
be a useful indicator of relapse. Our
patients also showed falls in all the
immunoglobulin classes (G, AandM) moni-
tored over the period of study. When
splenectomy and therapy status were
taken into account there were no differ-
ences between groups in respect of cellular
immunity but low values of IgG and IgM
were a particular feature of the chemo-
therapy/splenectomy group.
The clinical significance ofthe depressed
in vitro responses is difficult to evaluate
since there have beenno large-scale clinico-
immunological correlative studies. In our
own small study there were no serious
infections in those patients attaining
remission. Herpes/varicella infections were
common in that 6/27 patients (22%) were
affected (invariably within 2 years of
presentation). In the initial stages of the
study 3 patients who had had splenectomy
died of septicaemia (Hancock et al., 1976),
but since then no further patients have
had major problems with sepsis though it
is recognized that infections may arise
several years after splenectomy and the
relevance of the persistently low IgM
levels in our patients remains to be seen.
Splenectomy has been claimed to have
"protective" effects on peripheral leu-
cocyte counts during therapy and our
earlier study (Hancock et al., 1977)
confirmed this. At 5 years, however, the
neutrophil count was unchanged only in
the radiotherapy/splenectomy group com-
pared with the decreased level in other
patients. However, total lymphocyte
counts at 5 years were significantly higher
in both splenectomy groups.
The discrepancies between the increased
total-lymphocyte and T-lymphocyte levels
compared with depressed in vitro lympho-
cyte function in remission is difficult to
explain and this is further complicated by
reports of normal skin-test reactivity in
other series (Kun & Johnson, 1975; Fisher
et al., 1980). However, the non-concord-
ance ofthe various methods of assessment
ofimmunity is well recognized and it may
well be that different aspects of the
immunological system are variably affec-
ted by the therapeutic regimes being used
or that such immune defects are peculiar
to patients with Hodgkin's disease. It is
known, for example, that prolonged
defects in immunity are not usually found
in patients with non-Hodgkin's lymphoma
having similar chemotherapeutic regimes
(Fisher et al., 1980).
It has been suggested that certain
aspects of T-cell function, rather than
being depressed by the presence of soluble
factors, may in fact be affected by either
suppressor T cells or suppressor monocytes
and certainly increased sensitivity to
normal monocyte suppressor cells regu-
lating mixedlymphocyte culture responses
has been observed (Fisher et al., 1981). In
this context it is interesting to note the
significant increase in the monocyte count
over the period of remission in our
patients.
It seems then that persistent defects in
both cellular and humoral immune sys-
tems are seen during the 5 years following
treatment of Hodgkin's disease. Such
findings, particularly when taken together
with the American (Fuks et al., 1976;
Fisher et al., 1980) and Swedish
(Bjorkholm et al., 1977a, b) studies show-
ing prolonged abnormalities in T-lympho-
cyte function, favour the hypothesis of a
constitutional, rather than just a disease
and/or treatment-mediated defect. Hum-
oral defects are more a feature of patients
having splenectomy and chemotherapy.
However, there has been no excess of
infections in this small group and the
clinical relevance of our findings remains
to be determined.
We are grateful to the consultant medical staff of
Weston Park Hospital whose patients have been
studied, and to the Cancer Research Campaign
(Yorkshire Branch) for financial assistance.
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APPENDIX
INTENSIVE CYCLICAL
CHEMOTHERAPY
Modified MOPP regime
Mustine 6 mg/m2 i.v. )
Vincristine (Oncovin) - Days 1 and 8
1-4mg/M2 i.v. J
Oralprocarbazine 100mg/2 Days 1 and 14
Oral prednisolone 40 mg/day j
Six courses beginning at 28-day intervals.
Then4 further courses at 3-monthly intervals.
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